DDO-5936 (C09-1126-634)

DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancerIn VitroDDO-5936 is a Hsp90-Cdc37 PPI inhibitor with potency and specificity through binding to a critical site on Hsp90 involving Glu47. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoDDO-5936 (0~80 mg/kg; p.o.) shows effect at the high dose group . DDO-5936 is well tolerated for the absence of serious weight loss. DDO-5936 high dose groups show that tumor cells in the xenografts decreased significantly. DDO-5936 shows limited oral efficiency . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 0~80 mg/kg Administration: P.o. Result: Showed a moderate effect at the high dose group.IC50& Target:Hsp90-Cdc37 PPI. Specification: 10mM in DMSO Molecular Formula: C25H29N5O4S Molecular Weight: 495.6